Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 15/20 | 0.44 |
| ▸ | CTSK | P43235 | 14/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29215277 | 0.85 | CAPN1 (0.52) | CAPN1CTSSCTSKACEMEN1 | |
| SCHEMBL29215275 | 0.85 | CAPN1 (0.52) | CAPN1CTSSCTSKACEMEN1 | |
| SCHEMBL607528 | 0.84 | CAPN1 (0.53) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL10191368 | 0.84 | CAPN1 (0.53) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL25270770 | 0.83 | CAPN1 (0.49) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL25229415 | 0.83 | CAPN1 (0.49) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL25277223 | 0.81 | CAPN1 (0.50) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL16118847 | 0.81 | CAPN1 (0.50) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL3661740 | 0.81 | CAPN1 (0.51) | CAPN1CTSSCTSKMEN1GAA | |
| SCHEMBL3661736 | 0.81 | CAPN1 (0.51) | CAPN1CTSSCTSKMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217621-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2015-04-22 | — | — | EP | disclosed |
| US-8710000-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-04-29 | — | — | US | disclosed |
| US-20100279931-A1 | Insulin Derivative | NOVO NORDISK A/S | 2010-11-04 | — | — | US | disclosed |
| EP-2217621-A1 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060071-A1 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | WO | disclosed |
| EP-2058330-A1 | Insulin derivative | NOVO NORDISK A/S (DK) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279931-A1 | Insulin Derivative | IAPP, INSR, GPR119 | CAPN1 3586/4885CTSS 4077/4885CTSK 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.